Technical Analysis for IOVA - Iovance Biotherapeutics, Inc.

Grade Last Price % Change Price Change
grade A 15.03 -1.64% -0.25
IOVA closed down 1.64 percent on Friday, May 17, 2019, on 2.07 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical IOVA trend table...

Date Alert Name Type % Chg
Jack-in-the-Box Bullish Bullish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
MACD Bullish Signal Line Cross Bullish -1.64%
Expansion Breakout Bullish Swing Setup -1.64%
Expansion Pivot Buy Setup Bullish Swing Setup -1.64%
Pocket Pivot Bullish Swing Setup -1.64%
Volume Surge Other -1.64%

Older signals for IOVA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.
Medicine Biopharmaceutical Cancer Clinical Medicine Immunotherapy Oncology Cancer Treatments Cancer Immunotherapy Antineoplastic Drugs Melanoma Cell Therapy Metastatic Melanoma Solid Tumor Adoptive Cell Transfer Cancer Immunotherapy Products Head And Neck Cancers Breast And Lung Cancer National Cancer Institute Ocular Melanoma Treatment Of Metastatic Melanoma
Is IOVA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 18.25
52 Week Low 7.26
Average Volume 1,417,873
200-Day Moving Average 10.9597
50-Day Moving Average 10.926
20-Day Moving Average 11.4495
10-Day Moving Average 11.764
Average True Range 0.9713
ADX 18.62
+DI 46.7243
-DI 11.0736
Chandelier Exit (Long, 3 ATRs ) 13.6661
Chandelier Exit (Short, 3 ATRs ) 13.0639
Upper Bollinger Band 13.9865
Lower Bollinger Band 8.9125
Percent B (%b) 1.21
BandWidth 44.316346
MACD Line 0.5941
MACD Signal Line 0.2132
MACD Histogram 0.3809
Fundamentals Value
Market Cap 1.08 Billion
Num Shares 71.5 Million
EPS -2.08
Price-to-Earnings (P/E) Ratio -7.23
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.68
Resistance 3 (R3) 16.74 16.24 16.41
Resistance 2 (R2) 16.24 15.82 16.22 16.31
Resistance 1 (R1) 15.64 15.56 15.39 15.58 16.22
Pivot Point 15.14 15.14 15.02 15.12 15.14
Support 1 (S1) 14.54 14.72 14.29 14.48 13.84
Support 2 (S2) 14.04 14.46 14.02 13.75
Support 3 (S3) 13.44 14.04 13.66
Support 4 (S4) 13.38